Encision revenue, earnings up

BOULDER — Encision Inc. (OTC: ECIA) posted net revenue of $2.1 million and net income of $360,000 in its fiscal 2022 second quarter compared with $1.9 million and $9,000 year-over-year.

The medical device maker said in an earnings press release that the increase was due to “services performed under a Master Services Agreement with Auris Health Inc.”

Encision’s “active electrode monitoring” technology can prevent “dangerous radiant energy burns in minimally invasive surgery” the release said. In August, the company signed a three-year deal to sell products with that technology to Auris. Auris is owned by New Jersey-based Johnson & Johnson.

SPONSORED CONTENT

How dispatchable resources enable the clean energy transition

Platte River must prepare for the retirement of 431 megawatts (MW) of dispatchable, coal-fired generation by the end of the decade and address more frequent extreme weather events that can bring dark calms (periods when there is no sun or wind).

Encision said gross margins declined during the quarter to 45% from 53% year-over-year because of higher material costs.

It also received forgiveness of a $533,000 Paycheck Protection Program loan in the quarter, which it booked as “extinguishment of debt income.”

Envision trades on the Pink Sheets at a market cap of about $17 million.